Therapy News and Research

RSS

Clinical trial to test combination of two drugs in treating fibromyalgia

A chronic pain condition and numerous gastrointestinal disorders may all be caused by a virus. That's a Tuscaloosa-based surgeon's theory likely headed for a clinical trial early next year and one drawing support from a University of Alabama researcher who studies how viruses replicate.

6 Sep 2012

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

The drug telaprevir has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether telaprevir offers an added benefit compared with the present standard therapy.

6 Sep 2012

Scripps Florida designs new compound that shows promise against tremor ataxia syndrome

Scientists on the Florida campus of The Scripps Research Institute have designed a compound that shows promise as a potential therapy for one of the diseases closely linked to fragile X syndrome, a genetic condition that causes mental retardation, infertility, and memory impairment, and is the only known single-gene cause of autism.

6 Sep 2012

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

AMAG Pharmaceuticals, Inc. today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

6 Sep 2012

FDA continues review of Salix’s Crofelemer new drug application

Napo Pharmaceuticals, Inc. was informed today that the Food and Drug Administration is continuing its review of the new drug application seeking approval of crofelemer for the treatment of chronic diarrhea in people living with HIV/AIDS on anti-retroviral therapy.

6 Sep 2012

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

6 Sep 2012

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients.

6 Sep 2012

Janssen receives FDA Priority Review for bedaquiline NDA to treat MDR-TB

Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for bedaquiline (TMC207) to treat pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults as part of combination therapy.

6 Sep 2012

Kinetic Concepts launches Skin IQ 1000 MCM to help prevent and treat stage I-IV pressure ulcers

Kinetic Concepts, Inc. (KCI) announced today the U.S. launch of the Skin IQ 1000 Microclimate Manager (MCM) by its Therapeutic Support Systems (TSS) business.

6 Sep 2012

Corticosteroids needed after DALK to avert stromal rejection

Like those undergoing penetrating keratoplasty, patients treated with deep anterior lamellar keratoplasty may benefit from taking postoperative corticosteroids to prevent stromal rejection, report US researchers.

5 Sep 2012

Voice therapy should be offered to more thyroidectomy patients

Voice problems following surgery to remove the thyroid gland are a common problem reported by patients, but only a minority are offered voice therapy, show results from a US study.

5 Sep 2012

On-the-spot test aids postsurgical coagulopathy management

Point-of-care thromboelastometric and aggregometric testing helps to reduce exposure to allogenic blood products in patients with coagulopathy after cardiac surgery, a randomized trial shows.

5 Sep 2012

Biomarker predicts temsirolimus benefit in renal cancer

In patients with metastatic renal cell carcinoma, the biomarker serum lactate dehydrogenase is both prognostic for survival and predictive for the survival benefit conferred by the TORC1 inhibitor temsirolimus, research shows.

5 Sep 2012

Real-time prescription system reduces inappropriate prescribing of medications

A centralized prescription network providing real-time information to pharmacists in British Columbia, Canada, resulted in dramatic reductions in inappropriate prescriptions for opioid analgesics and benzodiazepines, widely used and potentially addictive drugs. The findings are reported in a study in CMAJ (Canadian Medical Association Journal).

5 Sep 2012

People with generalized anxiety disorder have weak brain connections

A new University of Wisconsin-Madison imaging study shows the brains of people with generalized anxiety disorder (GAD) have weaker connections between a brain structure that controls emotional response and the amygdala, which suggests the brain's "panic button" may stay on due to lack of regulation.

5 Sep 2012

NeuroSigma's external Trigeminal Nerve Stimulation system awarded CE Certification

NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS) system, called the Monarch, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older.

5 Sep 2012

Sleep apnoea severity associated with increased cancer mortality

Sleep apnoea severity has been associated with increased cancer mortality in a new study.

5 Sep 2012

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it has initiated the first of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel blocker for the treatment of chronic neuropathic pain indications.

5 Sep 2012

ARGO Medical, Cyclone Technologies announce availability of ReWalk exoskeleton system

Exoskeleton technology leader, ARGO Medical Technologies, along with mobility solutions provider, Cyclone Technologies, announced today that Claire Lomas has become the first person to take home an exoskeleton system for personal use.

5 Sep 2012

Therapy News and Research

Clinical trial to test combination of two drugs in treating fibromyalgia

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

Scripps Florida designs new compound that shows promise against tremor ataxia syndrome

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

FDA continues review of Salix’s Crofelemer new drug application

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Janssen receives FDA Priority Review for bedaquiline NDA to treat MDR-TB

Kinetic Concepts launches Skin IQ 1000 MCM to help prevent and treat stage I-IV pressure ulcers

Corticosteroids needed after DALK to avert stromal rejection

Voice therapy should be offered to more thyroidectomy patients

On-the-spot test aids postsurgical coagulopathy management

Biomarker predicts temsirolimus benefit in renal cancer

Real-time prescription system reduces inappropriate prescribing of medications

People with generalized anxiety disorder have weak brain connections

NeuroSigma's external Trigeminal Nerve Stimulation system awarded CE Certification

Sleep apnoea severity associated with increased cancer mortality

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

ARGO Medical, Cyclone Technologies announce availability of ReWalk exoskeleton system

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News